Price Alert

Arvinas Inc. (ARVN)

NASDAQ: ARVN · Real-Time Price · USD

7.13

0.05 (0.71%)

At close: Aug 15, 2025, 1:15 PM

0.71% (1D)

Bid	5.15
Market Cap	523.1M
Revenue (ttm)	372.8M
Net Income (ttm)	-72.6M
EPS (ttm)	-1.01
PE Ratio (ttm)	-7.05
Forward PE	-2.08
Analyst	Buy

Ask	7.16
Volume	527,001
Avg. Volume (20D)	2,412,463.6
Open	7.16
Previous Close	7.08
Day's Range	7.06 - 7.26
52-Week Range	5.90 - 29.61
Beta	2.23

About ARVN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ARVN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ARVN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Arvinas has released their quartely earnings on Aug 6, 2025:

Revenue of $22.4M misses estimates by $17.43M, with -70.72% YoY decline.

EPS of -0.84 exceeds estimates by 0.04, with -71.43% YoY decline.

Next Earnings Release

Arvinas Inc. is scheduled to release its earnings on Oct 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-15.51%

Arvinas shares are trading lower after the company... Unlock content with Pro Subscription

2 months ago

+8.82%

Arvinas shares are trading higher after the company announced its submission of an NDA to the FDA for Vepdegestrant

News

1 week ago · seekingalpha.com

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.

1 week ago · zacks.com

Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.49 per share a year ago.

1 month ago · zacks.com

Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positi...

2 months ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advise...

2 months ago · reuters.com

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, according t...

2 months ago · zacks.com

Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?

The consensus price target hints at a 94.9% upside potential for Arvinas (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

2 months ago · businesswire.com

Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN)

NEW YORK--(BUSINESS WIRE)---- $ARVN #CLASSACTIONLAWSUIT--The law firm of Kirby McInerney LLP reminds investors that the firm is investigating potential claims against Arvinas, Inc. (“Arvinas” or the “...

3 months ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...

3 months ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. ("Arvinas" or "the Company") (NASDAQ:ARVN)...